Breaking News, Collaborations & Alliances

Evotec, Takeda Enter Multi-Target Pact

Evotec AG has entered into a collaboration with Takeda Cambridge Ltd., to identify small molecule modulators against GPCR and Protease targets to treat various CNS and Metabolic diseases.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Evotec AG has entered into a collaboration with Takeda Cambridge Ltd., to identify small molecule modulators against GPCR and Protease targets to treat various CNS and Metabolic diseases. Financial terms were not disclosed. Evotec will apply its screening platform and GPCR modeling software to identify and validate novel modulators against various targets selected by Takeda. Dr. Mario Polywka, chief operating officer at Evotec said, “We are proud to be selected by Takeda Cambridge to collabor...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters